The NanoCont™ Drug Development Platform

Enabling the Next Generation of Clinically Meaningful, Scalable Drug Products

NanoCont™ is MAA Laboratories’ proprietary nanoparticle drug delivery and continuous manufacturing platform, purpose-built to address the most persistent challenges in pharmaceutical development—low solubility, poor bioavailability, dose-related toxicity, and formulation limitations. Whether applied to marketed drugs or pipeline compounds, NanoCont™ enables the creation of differentiated, patent-protected drug products with enhanced performance and real-world clinical value.

This scalable, platform-based technology is compatible with all dosage forms and applicable across all therapeutic areas—from oncology and immunology to CNS, cardiovascular, and rare diseases.

? Global-Ready Intellectual Property & Lifecycle Innovation

NanoCont™ provides a powerful tool for both life-cycle management and new drug development:

• For marketed products, the platform enables reformulation to resolve known performance liabilities (e.g., food effects, poor absorption, GI toxicity) and generate new intellectual property—extending product life and enhancing clinical relevance.

• For investigational compounds, NanoCont™ overcomes formulation hurdles such as poor solubility, bioavailability, and dose proportionality, enabling consistent dosing, improved patient tolerability, and faster advancement from preclinical through clinical stages.

All NanoCont™-enabled products are designed for regulatory success, aligning with global expectations for quality, performance, and scalability.

? How NanoCont™ Works

At the core of the NanoCont™ platform is a mechanical nanonization and polymer-coating process, where pharmaceutical crystals are ground to submicron sizes and stabilized using a patented surface-coating technology.

This nanonization dramatically increases the surface-area-to-volume ratio of the drug, resulting in:

• Faster and more complete dissolution

• Enhanced solubility

• Improved systemic absorption

• Greater formulation flexibility across dosage forms (e.g., oral, injectable, transdermal, pediatric)

The technology is optimized using a customized formulation strategy that targets the specific clinical, commercial, and regulatory goals of each product.

? NanoCont™ Delivers a Range of Transformational Benefits:

• ✅ Enhanced therapeutic efficiency with lower doses

• ✅ Improved solubility and bioavailability for poorly soluble drugs

• ✅ Restored dose proportionality for linear PK behavior

• ✅ Minimized or eliminated food effects

• ✅ Reduced inter-patient variability, improving compliance and predictability

• ✅ Mitigated adverse effects through lower Cmax or optimized tissue targeting

• ✅ Controlled or targeted-release profiles for better efficacy and convenience

• ✅ Formulation flexibility—e.g., converting injectables to oral tablets or capsules

• ✅ New IP opportunities and improved market positioning

? Why Choose NanoCont™

With proven clinical strategies approved by the U.S. FDA, and regulatory engagement spanning the U.S., Europe, Canada, and beyond, NanoCont™ is more than just a formulation solution—it’s a commercially viable, regulatory-ready platform that bridges cutting-edge science with real-world patient outcomes.

Whether you’re looking to revitalize existing assets or accelerate development of new molecular entities, NanoCont™ can unlock the full potential of your drug candidates.

? Partner with MAA Laboratories to bring NanoCont™-enabled therapies to patients worldwide.

Let us show you how NanoCont™ can transform your product pipeline—from lab to launch.